A study in the August 1 issue of the journal Sleep shows that people with severe sleep apnea have a much higher mortality risk than people without sleep apnea, and this risk of death increases when sleep apnea is untreated.
Results show that people who have severe sleep apnea, which involves frequent breathing pauses during sleep, have three times the risk of dying due to any cause compared with people who do not have sleep apnea. This sleep apnea risk is represented by an adjusted hazard ratio of 3.2 after controlling for age, sex and body mass index. When 126 participants who reported regular use of continuous positive airway pressure (CPAP) therapy were removed from the statistical analysis, the hazard ratio for all-cause mortality related to severe sleep apnea rose to 4.3.
“We found that both men and women with sleep apnea in the general population – not patients – mostly undiagnosed and untreated, had poorer survival compared with persons without sleep apnea, given equal BMI, age and sex,” said principal investigator and lead author Terry Young, PhD, professor of epidemiology at the University of Wisconsin-Madison.
Clinical trials are carefully controlled research studies in which people volunteer to test the safety and effectiveness of new drugs, medical products or techniques. Each study gathers scientific evidence to find better ways to prevent, diagnose or treat medical conditions. In the U.S., all drugs undergo rigorous clinical trials before being approved for use by the general public.
Clinical trials are an integral part of medicines and devices getting approved for use. In addition, many people enrolled in clinical trials have been helped as a result of having access to leading-edge care they otherwise would not have had. Quite often the first people to have been helped by a medication or medical device are people who were part of its clinical trial, learn more about clinical trial services for drug development.
Clinical Trials at the Sleep Therapy & Research Center
At the Sleep Therapy & Research Center, we have been one of the only research centers for sleep disorders in San Antonio since 2006. We have conducted numerous clinical trials over the years and helped companies launch drugs and products that have subsequently improved the health and lives of thousands of patients suffering from sleep disorders.
If you are interested in enrolling in a clinical trial, sign up now. One of our staff will contact you to let you know if you meet the qualifications for participating in one of our studies.
According to Young, most previous studies of sleep apnea and mortality have involved patients referred for a clinical sleep diagnostic evaluation; the mortality risk for sleep apnea in the general population has not been previously reported. Check out these meticore reviews.
The study was an 18-year follow-up of 1,522 participants in the ongoing Wisconsin Sleep Cohort Study, which was established in 1988 and involved a random sample of men and women from the community who were between the ages of 30 and 60 when the study began. After spending one night at the University of Wisconsin General Clinical Research Center for assessment by polysomnography, participants were categorized by apnea-hypopnea index (AHI), which is the average number of breathing pauses (apneas) and reductions (hypopneas) per hour of sleep. Sixty-three individuals (about four percent) had severe sleep apnea at baseline with an AHI of 30 or more and a range of 30 to 97 apneas and hypopneas per hour. About 76 percent of the study group (1,157 individuals) had no sleep apnea with an AHI of less than five.
For the follow-up study, state and national death records were reviewed up to March 1, 2008, to identify participants who had died and to note the causes of death listed on the death certificates. Eighty deaths were recorded, including 37 deaths attributed to cancer and 25 deaths attributed to cardiovascular disease and stroke.
About 19 percent of participants with severe sleep apnea died (12 deaths), compared with about four percent of participants with no sleep apnea (46 deaths). Although participants with mild sleep apnea (AHI of five to 14) or moderate sleep apnea (AHI of 15 to 29) had a mortality risk that was 50 percent greater than those with no sleep apnea, the results did not achieve statistical significance.
Hazard ratios for all-cause mortality remained high after further adjustments for other factors such as smoking, alcohol use, sleep duration and total cholesterol. Severe sleep apnea was associated with increased mortality whether or not participants experienced daytime sleepiness.
About 42 percent of deaths in people with severe sleep apnea (5 of 12 deaths) were attributed to cardiovascular disease or stroke, compared with 26 percent of deaths in people with no sleep apnea (12 of 46 deaths). When the 126 participants who reported regular CPAP use were removed from the analysis, the hazard ratio for cardiovascular mortality soared from 2.9 to 5.2 for people with severe sleep apnea. The results suggest that regular CPAP use may protect sleep apnea patients against cardiovascular death. Improve your healthy dietary results with Nutrisystem.
“I was surprised by how much the risks increased when we excluded people who reported treatment with CPAP,” Young said. “Our findings suggest – but cannot prove – that people diagnosed with sleep apnea should be treated, and if CPAP is the prescribed treatment, regular use may prevent premature death.”
Statistical adjustments show that high blood pressure, cardiovascular disease, stroke and diabetes may play a role in the association between sleep apnea and mortality, but the specific mechanisms by which sleep apnea contributes to mortality remain unclear.
The study was supported by grants from the National Institutes of Health.
According to the American Academy of Sleep Medicine, obstructive sleep apnea (OSA) involves a decrease or complete halt in airflow despite an ongoing effort to breathe. It occurs when the muscles relax during sleep, causing soft tissue in the back of the throat to collapse and block the upper airway.
The most common treatment for OSA is CPAP therapy, which provides a steady stream of air through a mask that is worn during sleep. This airflow keeps the airway open to prevent pauses in breathing and restore normal oxygen levels.
Sleep is the official journal of the Associated Professional Sleep Societies, LLC, a joint venture of the American Academy of Sleep Medicine and the Sleep Research Society.